

AHA Highlights 2023

Recorded Live on:

Tuesday, December 5

7:30 – 9:00 pm EST



Developed by:



AHA Highlights 2023: Live Webcast



CO-CHAIRS

Milan Gupta,
MD, FRCPC, FCCS, CPC(HC)
Assistant Professor, Department
of Medicine, University of Toronto
Medical Director, Canadian
Collaborative Research Network
Brampton, ON



CO-CHAIRS

Narendra Singh,
MD, FRCPC, FCCS, FACC, FAHA
Director, NSC Cardiology
Clinical Assistant Professor,
Medical College of Georgia at
Augusta University and Mercer
University
Atlanta, GA

This program will cover the key clinical trial findings and their implications from AHA 2023. This program is intended for cardiovascular specialists and primary care physicians from across Canada.

Discussion Topics:

Trials to be discussed:

- **SELECT** – Semaglutide in patients with CAD and obesity: a new era in CV risk management?
- **ORBITA-2** – Does coronary stenting improve CV outcomes in stable angina?
- **AZALEA** – Is a factor XI inhibitor truly safer than rivaroxaban in atrial fibrillation?
- **ARTESIA/NOAH-AFNET 6** – Do we need to anticoagulate patients with subclinical atrial fibrillation?

Learning Objectives:

Following participation in this program, participants will be able to:

- Identify the clinical implications of the new data presented at AHA 2023
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice



This program was developed by CCRN and received an unrestricted educational grant from Novo Nordisk and Anthos Therapeutics.

Watch the recording on CCRN

<https://www.ccrnmd.com/webcasts>

